You are here: Industry Insights > Pharmaxis

News List

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model prnasia
August 05, 2021
Clinical stage drug development company Pharmaxis Ltd today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) ...
EffRx Signs Agreement with Pharmaxis for Registration, Commercialization of Bronchitol® americanpharmaceuticalreview
June 14, 2019
EffRx Pharmaceuticals has entered into an exclusive license agreement with Pharmaxis, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® (mannitol) for cystic fibrosis in Switzerland.
Pharmaxis Announces Resubmission of Bronchitol NDA drugs
December 26, 2018
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the resubmission of the Bronchitol New Drug Application with the United States Food and Drug Administration (FDA) by its licensee Chiesi Group (Chiesi).
Pharmaxis Releases Positive Results of for LOXL2 Trial americanpharmaceuticalreview
October 12, 2018
Pharmaxis announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fib